Keros Therapeutics Set to Join Russell 2000® Index
June 26, 2020 07:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass, June 26, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual Meeting
June 12, 2020 07:01 ET
|
Keros Therapeutics, Inc.
Poster presentation highlights Phase 1 clinical trial data demonstrating tolerability, pharmacokinetics and pharmacodynamics of KER-050 in healthy postmenopausal women.Poster presentations introduce...
Keros Therapeutics To Present At The Jefferies 2020 Virtual Healthcare Conference
May 28, 2020 07:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
May 22, 2020 07:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 22, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics to Present at the Virtual 25th Annual Congress of the European Hematology Association
May 14, 2020 09:15 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 13, 2020 16:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Receives $23 million Series B Funding for Development of Therapies to Treat Debilitating Neuromuscular Diseases
January 07, 2019 07:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Keros Therapeutics, a company dedicated to the discovery and development of novel therapeutics for neuromuscular diseases, announced a $23 million...